Days after Merck deal, Sutro rolls out $85M E round to fund internal cancer pipeline
Just days after announcing a deal with Merck, South San Francisco’s Sutro BioPharma is trotting out a sizable infusion of cash today to fuel its own internal pipeline of cancer drugs.
The company says it’s raised $85.4 million from a rather lengthy list of investors to push two early-stage programs through the clinic. Sutro, though, is probably better known for its manufacturing tech, which allows them to produce therapeutic proteins without using live cells as miniature factories. That’s particularly useful for speeding up discovery and development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.